We are pleased to announce that Biotech Connect (BTC) has officially joined LabX Media Group (LMG). Together, we are bigger, stronger, and better positioned to provide innovative solutions that improve the value of your products and services.
Started in 1995, LabX Media Group is a diversified global media company for the laboratory professional. In addition to its flagship LabX (the largest marketplace for buying and selling scientific products), the Group includes Lab Manager, LabWrench and The Scientist, which together represent an unmatched editorial environment and interactive community for the biotech industry.
LMG will complement BTC’s existing event services by providing comprehensive and innovative solutions to increase your products’ awareness and visibility within your targeted research audience. LMG will function as a turn-key solutions provider to maximize your return on investment from both a marketing and a sales perspective.
“It is very exciting to be working with the high energy and experience of Simon and Guillaume,” said Bob Kafato, president of LMG. “Our acquisition of BTC complements our overall offerings so we can now provide multiple media platforms to the research marketplace. This investment represents an important strategic opportunity to connect attendees of BTC events with the audience of The Scientist, Lab Manager and LabX.com, and LMG will be able to help BTC achieve higher attendee numbers and attract more vendors.”
From our perspective, there is a natural fit between the activities of BTC and the strategic positioning of LMG as a media company for the laboratory professional. Our capability and know-how in the event organization sector will greatly synergize with the cross-platform publishing expertise of LMG. Joining LMG will definitely help us establish a strong foothold in Canada and the US and, at the same time, will enable our customers to benefit from a more diversified portfolio of products and services. We are excited to be part of LMG and eager to contribute to its advancement and that of the life science industry.
If you have any questions about this new venture, please don’t hesitate to contact us.
Sincerely, Guillaume and Simon